SCHEMBL15069907

SCHEMBL15069907

CC(=O)c1cnc(-n2cnc(C)c2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR2E1 Q9Y466 3/20 0.38
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
CYP2E1 P05181 1/20 0.36
CYP2A6 P11509 1/20 0.36
ALPL P05186 2/20 0.33
LMNA P02545 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
PLAA Q9Y263 1/20 0.33
KCNJ1 P48048 1/20 0.33
LDLR P01130 1/20 0.33
PCSK9 Q8NBP7 1/20 0.33
ALPG P10696 1/20 0.33
MAPK13 O15264 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15069906 0.83 ALPL (0.36) NR2E1PDE4APDE4BPDE4CPDE4D
SCHEMBL12796813 0.77 CYP2E1 (0.41) NR2E1PDE3BPDE3ACYP2E1CYP2A6
SCHEMBL15069900 0.76 PSEN1 (0.42) NR2E1PDE4APDE4BPDE4CPDE4D
SCHEMBL3426851 0.74 KCNJ1 (0.54) NR2E1PDE4APDE4BPDE4CPDE4D
SCHEMBL1672090 0.72 PDE4A (0.37) NR2E1PDE4APDE4BPDE4CPDE4D
SCHEMBL12796759 0.72 CYP1A2 (0.38) NR2E1PDE3BPDE3ACYP2E1CYP2A6
SCHEMBL12913454 0.72 CYP2E1 (0.37) NR2E1PDE3BPDE3ACYP2E1CYP2A6
Lithium Ion SCHEMBL1672091 0.71 PDE4A (0.36) NR2E1PDE4APDE4BPDE4CPDE4D
SCHEMBL1671821 0.71 PSEN1 (0.43) MAOAMAOB
SCHEMBL8295724 0.71 PDE4A (0.59) NR2E1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403815-B2 Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-08-02 US disclosed
US-20130165416-A1 COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165416-A1 COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS IAPP, APP, BACE1 NR2E1 3891/4885PDE4A 791/4885PDE4B 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.